The short version of MC1R fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-31 and is reviewed periodically as new material appears.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
==== Crosstalk ==== Many known phosphorylation sites and O-GlcNAcylation sites are nearby each other or overlapping. As protein O-GlcNAcylation and phosphorylation both occur on serine and threonine residues, these post-translational modifications can regulate each other. For example, in CKIIα, S347 O-GlcNAc has been shown to antagonize T344 phosphorylation. Reciprocal inhibition, i.e., phosphorylation inhibition of O-GlcNAcylation and O-GlcNAcylation of phosphorylation, has been observed on other proteins including murine estrogen receptor β, RNA Pol II, tau, p53, CaMKIV, p65, β-catenin, and α-synuclein. Positive cooperativity has also been observed between these two post-translational modifications, i.e., phosphorylation induces O-GlcNAcylation or O-GlcNAcylation induces phosphorylation. This has been demonstrated on MeCP2 and HDAC1. In other proteins, e.g., cofilin, phosphorylation and O-GlcNAcylation appear to occur independently of each other. In some cases, therapeutic strategies are under investigation to modulate O-GlcNAcylation to have a downstream effect on phosphorylation. For instance, elevating tau O-GlcNAcylation may offer therapeutic benefit by inhibiting pathological tau hyperphosphorylation. Besides phosphorylation, O-GlcNAc has been found to influence other post-translational modifications such as lysine acetylation and monoubiquitination.
Fully aquatic mammals, the cetaceans and sirenians, have lost their legs and have a tail fin to propel themselves through the water. Flipper movement is continuous. Whales swim by moving their tail fin and lower body up and down, propellling themselves through vertical movement, while their flippers are mainly used for steering. Their skeletal anatomy allows them to be fast swimmers. Most species have a dorsal fin to prevent themselves from turning upside-down in the water. The flukes of sirenians are raised up and down in long strokes to move the animal forward, and can be twisted to turn. The forelimbs are paddle-like flippers which aid in turning and slowing. Semi-aquatic mammals, like pinnipeds, have two pairs of flippers on the front and back, the fore-flippers and hind-flippers. The elbows and ankles are enclosed within the body. Pinnipeds have several adaptions for reducing drag. In addition to their streamlined bodies, they have smooth networks of muscle bundles in their skin that may increase laminar flow and make it easier for them to slip through water. They also lack arrector pili, so their fur can be streamlined as they swim. They rely on their fore-flippers for locomotion in a wing-like manner similar to penguins and sea turtles. Fore-flipper movement is not continuous, and the animal glides between each stroke. Compared to terrestrial carnivorans, the fore-limbs are reduced in length, which gives the locomotor muscles at the shoulder and elbow joints greater mechanical advantage; the hind-flippers serve as stabilizers.
== Contraindications == Venlafaxine is not recommended in patients hypersensitive to it, nor should it be taken by anyone who is allergic to the inactive ingredients, which include gelatin, cellulose, ethylcellulose, iron oxide, titanium dioxide and hypromellose. It should not be used in conjunction with a monoamine oxidase inhibitor (MAOI), as it can cause potentially fatal serotonin syndrome. Venlafaxine might interact with tramadol or other opioids, as well as trazodone and buspirone, so caution is needed while mixing multiple serotonergic agents together.
Copper histidinate, sold under the brand name Zycubo, is a medication used for the treatment of Menkes disease. Copper histidinate is a copper replacement therapy given by subcutaneous injection. The most common side effects include infections, respiratory problems, seizures, vomiting, fever, anemia and injection site reactions. Copper histidinate was approved for medical use in the United States in January 2026.
Sources: en.wikipedia.org
Rockefeller University Council on Foreign Relations (CFR) – Especially the notable 1939–45 War and Peace Studies that advised the US State Department and the US government on World War II strategy and forward planning Royal Institute of International Affairs (RIIA) in London Carnegie Endowment for International Peace in Washington – Support of the diplomatic training program Brookings Institution in Washington – Significant funding of research grants in the fields of economic and social studies World Bank in Washington – Helped finance the training of foreign officials through the Economic Development Institute Harvard University – Grants to the Center for International Affairs and medical, business and administration Schools Yale University – Substantial funding to the Institute of International Studies Princeton University – Office of Population Research Columbia University – Establishment of the Russia Institute University of the Philippines, Los Baños – Funded research for the College of Agriculture and built an international house for foreign students McGill University – The Rockefeller Foundation funded the Montreal Neurological Institute, on the request of Wilder Penfield, a Canadian neurosurgeon, who had met David Rockefeller years before Library of Congress – Funded a project for photographic copies of the complete card catalogues for the world's fifty leading libraries Bodleian Library at Oxford University – Grant for a building to house five million volumes Population Council of New York – Funded fellowships Social Science Research Council – Major funding for fellowships and grants-in-aid National Bureau of Economic Research National Institute of Public Health of Japan (formerly The Institute of Public Health (国立公衆衛生院, Kokuritsu Kōshū Eisei-in) "School of Public Health"ja) in Tokyo (1938) Group of Thirty – In 1978 the foundation invited Geoffrey Bell to set up this high-powered and influential advisory group on global financial issues, whose former chairman was longtime Rockefeller associate Paul Volcker, until his death in 2019 London School of Economics – funded research and general budget Geneva Graduate Institute of International Studies – funded general budget from 1927 to 1954 University of Lyon, France – funded research in natural sciences, social sciences, medicine and the new building of the medical school during the 1920s–1930s The Trinidad Regional Virus Laboratory The Results for Development Institute – funded the Center for Health Market Innovations Mahidol University in Thailand VoteRiders – a nationwide nonprofit founded in 2012 to promote a resilient democracy through voter ID access
=== Constitutional framework and term length === The Constitution of the Bolivarian Republic of Venezuela, adopted in 1999, sets the presidential term at six years. Article 230 establishes the length of the term, while a 2009 constitutional amendment removed term limits for the presidency and other elected offices, allowing indefinite re-election. Article 231 provides that the president-elect must take office on 10 January of the first year of the term by swearing an oath before the National Assembly, or before the Supreme Tribunal of Justice when circumstances prevent inauguration before the legislature. Article 233 regulates the "absolute absence" of the president (due to death, resignation, removal by the TSJ, permanent incapacity, abandonment of office or recall by referendum). If such an absence occurs in the first four years of the term, a new presidential election must be called within 30 days and the executive vice-president assumes the presidency on an interim basis; in the last two years, the executive vice-president completes the term. If the president is only deemed "temporarily unavailable", the executive vice-president may temporarily assume the presidency for 90 days, and—subject to the approval of the National Assembly—this interim period may be extended by another 90 days, for a total of six months.
== See also == 2007 pet food recalls 2009 Chinese lead poisoning scandal 2013 Fonterra recall 2022 United States infant formula shortage Chinese protein export contamination Food safety in China Official test failures of the 2008 Chinese milk scandal Swill milk scandal Timeline of the 2008 Chinese milk scandal
=== RNA sequencing === RNA sequencing was one of the earliest forms of nucleotide sequencing. The major landmark of RNA sequencing is the sequence of the first complete gene and the complete genome of Bacteriophage MS2, identified and published by Walter Fiers and his coworkers at the University of Ghent (Ghent, Belgium), in 1972 and 1976. Traditional RNA sequencing methods require the creation of a cDNA molecule which must be sequenced.
== External links == Daintith, John (18 August 2008). Biographical Encyclopedia of Scientists (Third ed.). CRC Press. ISBN 978-1-4200-7272-3 – via Google Books. "Sidney W. Fox; Analyzed First Moon Rocks". 18 August 1998 – via LA Times. Fox, Sidney W.; Harada, Kaoru (1958). "Thermal Copolymerization of Amino Acids to a Product Resembling Protein". Science. 128 (3333): 1214. Bibcode:1958Sci...128.1214F. doi:10.1126/science.128.3333.1214. JSTOR 1756313. PMID 13592311. Fox, Sidney W. (1957). "The chemical problem of spontaneous generation". Journal of Chemical Education. 34 (10): 472. Bibcode:1957JChEd..34..472F. doi:10.1021/ed034p472.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.